However, the suppression of tumor growth with imatinib was greater in KLC2-WT mice than in the control and L523I mice on the 15th day of the treatment, with reductions of 39% and 25% observed in mice carrying KLC2-WT and L523I, respectively (Supplementary Fig. S7B). Here, KLC2 is linked to neoplasm.